Eli Lilly's Donanemab Secures MHRA Approval for Alzheimer's Treatment

Eli Lilly and Company, a pharmaceutical company that uses science to improve lives globally, has revealed that the Medicines and Healthcare products Regulatory Agency (MHRA) has approved the marketing of donanemab, an injection for intravenous infusion every four weeks, to help manage mild cognitive impairment and mild dementia caused by Alzheimer's disease in eligible adults in Great Britain.

Only individuals who are either heterozygotes for apolipoprotein E e4 (ApoE e4) or do not carry the gene are able to receive currently approved amyloid-targeting therapies in Great Britain. Donanemab is the sole therapy that targets amyloid plaques and has proof that treatment can be stopped once the plaques are eliminated. Great Britain, the third largest market, has given approval for donanemab, which is sold under the brand name Kisunla.

"People around the world want and deserve access to treatment options for this disease. This approval in Great Britain is another significant step to ensure patients with Alzheimer's disease can receive treatment with this new class of amyloid targeting therapies, which could give them more time in the early symptomatic stage of the disease to do what matters most to them," said Ilya Yuffa, executive vice president and president of Lilly International, Eli Lilly and Company. "Donanemab demonstrated meaningful results for people with early symptomatic Alzheimer's disease by significantly slowing cognitive and functional decline in our TRAILBLAZER-ALZ 2 study."